Gao Xin, Zhu Ying, Lv Tongdan, Luo Mingpeng, Jiang Yu, Sun Leitao, Zheng Shusen, Jiang Donghai, Ruan Shanming
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine) Hangzhou 310006, Zhejiang, China.
NHC Key Laboratory of Combined Multi-Organ Transplantation Hangzhou 310003, Zhejiang, China.
Am J Cancer Res. 2024 May 15;14(5):2390-2407. doi: 10.62347/ZBVG9125. eCollection 2024.
Colorectal cancer is one of the most common malignancies with a high incidence, metastatic tendency and low 5-year survival rate. Resveratrol, a polyphenolic compound has been shown to inhibit colorectal cancer metastasis in recent studies. Its underlying molecular mechanism remains to be elucidated. Our findings demonstrated that miR-125b-5p, acting as a tumor suppressor, was conspicuously down-regulated in both colorectal cancer tissues and cell lines. The expression of miR-125b-5p negatively correlated with the expression of its direct target TNF receptor associated factor 6 (TRAF6). Both miR-125b-5p overexpression and TRAF6 knockdown inhibited metastasis of colorectal cancer cells. In addition, we uncovered that resveratrol up-regulated miR-125b-5p by increasing its stability and suppressed TRAF6-induced signal pathway in a dose/time-dependent manner. Resveratrol could significantly curtail the migration and invasion of colorectal cancer cells, which was counteracted by miR-125b-5p knockdown or TRAF6 overexpression. These results indicated that resveratrol could restrain colorectal cancer metastasis by promoting miR-125b-5p/TRAF6 signaling axis. Furthermore, lung metastasis models of colorectal cancer were constructed by tail vein injection. Down-regulation of miR-125b-5p could facilitate colorectal cancer metastasis in vivo, which could be impeded by resveratrol. In conclusion, our findings delineated the miR-125b-5p/TRAF6 signaling axis as a novel molecular mechanism underlying the metastatic process in colorectal cancer, as well as a prospective therapeutic target. Resveratrol disrupts colorectal cancer metastasis by activating miR-125b-5p/TRAF6 signal pathway and might improve the clinical outcome of colorectal cancer patients with low expression of miR-125b-5p.
结直肠癌是最常见的恶性肿瘤之一,具有高发病率、转移倾向和低5年生存率。白藜芦醇是一种多酚类化合物,最近的研究表明它能抑制结直肠癌转移。其潜在的分子机制仍有待阐明。我们的研究结果表明,作为一种肿瘤抑制因子的miR-125b-5p在结直肠癌组织和细胞系中均显著下调。miR-125b-5p的表达与其直接靶点肿瘤坏死因子受体相关因子6(TRAF6)的表达呈负相关。miR-125b-5p过表达和TRAF6敲低均抑制结直肠癌细胞的转移。此外,我们发现白藜芦醇通过增加miR-125b-5p的稳定性上调其表达,并以剂量/时间依赖性方式抑制TRAF6诱导的信号通路。白藜芦醇可显著抑制结直肠癌细胞的迁移和侵袭,而miR-125b-5p敲低或TRAF6过表达可抵消这种作用。这些结果表明,白藜芦醇可通过促进miR-125b-5p/TRAF6信号轴抑制结直肠癌转移。此外,通过尾静脉注射构建了结直肠癌肺转移模型。miR-125b-5p的下调可促进结直肠癌在体内的转移,而白藜芦醇可抑制这种转移。总之,我们的研究结果阐明了miR-125b-5p/TRAF6信号轴是结直肠癌转移过程中的一种新的分子机制,也是一个有前景的治疗靶点。白藜芦醇通过激活miR-125b-5p/TRAF6信号通路破坏结直肠癌转移,可能改善miR-125b-5p低表达的结直肠癌患者的临床结局。